<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978636</url>
  </required_header>
  <id_info>
    <org_study_id>21-447</org_study_id>
    <nct_id>NCT04978636</nct_id>
  </id_info>
  <brief_title>Low Tidal Volume Ventilation With Hyperoxia Avoidance During Cardiopulmonary Bypass (The FOCUS Trial)</brief_title>
  <official_title>The eFfect of cOntinuous Low Tidal Volume Ventilation With Hyperoxia Avoidance During CardiopUlmonary Bypass &quot;FOCUS&quot; Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Cardiovascular Anesthesiologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-institutional study (CCF, UPMC, OSU) evaluating different ventilation&#xD;
      strategies during cardiopulmonary bypass on mortality and postoperative pulmonary&#xD;
      complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will evaluate the effect of low tidal volume with varying FiO2 fractions&#xD;
      during cardiopulmonary bypass on postoperative mortality and pulmonary complications. This&#xD;
      will be a prospective, pragmatic, cluster randomized trial including all eligible adult&#xD;
      cardiac surgical patients requiring cardiopulmonary bypass. Each week, all operating rooms&#xD;
      will be randomized to one of three possible ventilation strategies during the period of&#xD;
      cardiopulmonary bypass: 1) continuous low tidal volume ventilation with inspired oxygen&#xD;
      fraction at 1.0, 2) continuous low tidal volume ventilation with inspired oxygen fraction at&#xD;
      0.21, and 3) no ventilation (apnea).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Composite including STS 30 day Mortality and postoperative pulmonary complications</measure>
    <time_frame>Within 30 days of surgery</time_frame>
    <description>Composite including STS 30-day mortality and postoperative pulmonary complications defined a early respiratory failure defined as PaO2/FiO2 ratio&lt;200 mmHg at any time within the first 24 hours of ICU admission, postoperative reintubation during the hospital stay, prolonged ventilation, pneumonia, pleural effusion requiring drainage, pneumothorax requiring intervention, and readmission due to: pleural effusion requiring intervention, or pneumonia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CPB time</measure>
    <time_frame>During surgery</time_frame>
    <description>Duration of cardiopulmonary bypass (STS defined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU LOS</measure>
    <time_frame>Within 30 days of surgery</time_frame>
    <description>ICU length of stay (STS defined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early respiratory failure - PaO2/FiO2 ratio &lt; 200 mmHg at any time within the first 24 hours of ICU admission</measure>
    <time_frame>24 hours</time_frame>
    <description>PaO2/FiO2 ratio &lt; 200 mmHg at any time within the first 24 hours of ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital LOS</measure>
    <time_frame>Within 30 days of surgery</time_frame>
    <description>Hospital length of stay (STS defined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reintubation</measure>
    <time_frame>Within 30 days of surgery</time_frame>
    <description>Reintubation (STS defined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for tracheostomy</measure>
    <time_frame>Within 30 days of surgery</time_frame>
    <description>Need for tracheostomy (STS defined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pleural effusion requiring drainage</measure>
    <time_frame>Within 30 days of surgery</time_frame>
    <description>Pleural effusion requiring drainage (STS defined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia</measure>
    <time_frame>Within 30 days of surgery</time_frame>
    <description>Pneumonia (STS defined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>within 30 days of surgery</time_frame>
    <description>Readmission due to respiratory complication or need for thoracentesis and chest tube insertion (STS defined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>Within 30 days of surgery</time_frame>
    <description>STS defined in hospital mortality</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">5502</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Continuous low-tidal volume ventilation with using FiO2 of 0.21</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigator will investigate the effect of continuous low tidal volume ventilation with hyperoxia avoidance (using FiO2 of 0.21) on PPCs and 30-day mortality compared to low-tidal volume ventilation (with FiO2 of 0.21) or apnea during CPB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous low tidal volume ventilation with using FiO2 of 1.0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigator will investigate the effect of low tidal volume lung ventilation with hyperoxia avoidance (FiO2 of 0.21) on PPCs and mortality compared to hyperoxic low-tidal volume ventilation (with FiO2 of 1.0) or apnea during CPB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apnea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigator will investigate the effect of apnea during on PPCs and mortality compared to hyperoxic low-tidal volume ventilation (with FiO2 of 1.0) or hyperoxia avoidance (FiO2 of 0.21) during CPB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continuous low-tidal volume ventilation with using FiO2 of 0.21</intervention_name>
    <description>The continuous low-tidal volume ventilation with using FiO2 of 0.21 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 0.21 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients.</description>
    <arm_group_label>Continuous low-tidal volume ventilation with using FiO2 of 0.21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continuous low tidal volume ventilation with using FiO2 of 1.0</intervention_name>
    <description>The continuous low-tidal volume ventilation with using FiO2 of 1.0 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 1.0 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients.</description>
    <arm_group_label>Continuous low tidal volume ventilation with using FiO2 of 1.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Apnea During CPB</intervention_name>
    <description>There will be no ventilation used</description>
    <arm_group_label>Apnea</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years of age&#xD;
&#xD;
          -  Male and female patients undergoing elective cardiac surgeries requiring&#xD;
             cardiopulmonary bypass.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Emergency surgeries, surgeries requiring lung isolation and one-lung ventilation (OLV),&#xD;
        heart or lung transplants, and mechanical circulatory support device implantation pulmonary&#xD;
        thrombendarterectomies.&#xD;
&#xD;
          -  Surgeries requiring one-lung ventilation will be excluded because of the inability to&#xD;
             employ study intervention and the differential treatment of the lungs likely&#xD;
             confounding any potential effect from the planned intervention.&#xD;
&#xD;
          -  Lung transplant surgeries will be excluded for similar reasons as well as other&#xD;
             confounding effects affecting the primary composite outcome.&#xD;
&#xD;
          -  Heart transplants and mechanical circulatory support device implantation surgeries&#xD;
             will be excluded because these patients already receive intervention as part of the&#xD;
             institutional protocol at the primary study site.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Kelava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberta Johnson</last_name>
    <phone>216/444/9950</phone>
    <email>johnsor13@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esra Kutlu, MD</last_name>
    <phone>216-445-7530</phone>
    <email>KUTLUYE@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Johnson</last_name>
      <phone>216-444-9950</phone>
      <email>johnsor13@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Esra Kutlu, MD</last_name>
      <phone>216-445-7530</phone>
      <email>KUTLUYE@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Marta Kelava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

